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Abstract
Background
The effectiveness and safety of bisphosphonates treatment used in the young population
have not been well studied. Despite insufficient data on effectiveness and safety of bisphos-
phonates in young patients, bisphosphonates are still considered in younger patients at
high risk for osteoporosis or fracture. The objectives of this study were to identify bisphos-
phonate initiators aged 10–45 years and describe their clinical characteristics and to assess
time trends of bisphosphonate use over the past decade in a large U.S. population-based
cohort.
Methods
Using the medical and pharmacy claims data from a U.S. commercial insurance (2003–
2012), patients aged 10–45 years without malignancy who initiated an oral or intravenous
bisphosphonate after at least 1 year of insurance enrollment were selected. Baseline demo-
graphics, comorbidities, medications and health care utilization were assessed in the year
prior to initiating a bisphosphonate. The trend of bisphosphonate use over time was
examined.
Results
There were 9,082 bisphosphonate initiators (0.02% of the same agegroup in the population).
The mean age was 38.1 years and 79.6% female. Osteoporosis was the most common diag-
nosis (41.2%). At baseline, 10.8% had a diagnosis of fracture and 29.0% had a bone mineral
density measured. Of those who used glucocorticoids (39%) at baseline, the mean 1-year
cumulative prednisone-equivalent dose was 2,669 milligrams. The use of bisphosphonates
in the young population significantly decreased over the past decade (p<0.001).
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Among young patients aged 10–45, the use of bisphosphonates was uncommon and signif-
icantly decreased over the past decade in the U.S. While most patients initiating bisphos-
phonates had a diagnosis of osteoporosis and fracture in the preceding year, some had no
recorded claims with a diagnosis of fracture, osteoporosis, or long-term glucocorticoids use
at baseline. Future research is needed to examine the effectiveness and safety of bisphos-
phonates in young patients at risk for osteoporosis.
Introduction
More than one million patients had at least one claim for oral bisphosphonate prescription in
the US between 2001 and 2007.[1] Bisphosphonates are widely used as the first line therapy for
osteoporosis in postmenopausal women and older men based on efficacy data in reducing the
risk of osteoporotic fracture from randomized clinical trials.[2–4] However, data from ran-
domized controlled studies are not available for adolescents and young adults due to feasibility
and potential ethical issues.
Over the past decade, increasing data suggest potential safety issues associated with bisphos-
phonates such as osteonecrosis of the jaw, atrial fibrillation and atypical femur fracture.[5] The
positive effects of the bisphosphonates treatment may be counterbalanced by a decrease in tis-
sue heterogeneity, which could impair tissue mechanical properties.[6] To date, long-term
effects of bisphosphonates are not fully understood, [7] and the effects of bisphosphonates may
be different in developing bones in adolescents [8, 9]. Furthermore, there are safety concerns
for women of child bearing age, because animal studies suggest bisphosphonates as small mole-
cules may pass through the placenta and adversely affect fetal skeleton.[10] Use of bisphospho-
nates in women of child bearing age may be particularly problematic as a large portion of the
absorbed bisphosphonates dose is bound to bone with an estimated elimination half-life of
greater than 10 years, [11] and thus pre-pregnancy administration of bisphosphonates could
potentially result in embryonic exposure.
Long-term use of glucocorticoids is associated with morbid complications including a de-
cline in bone mineral density (BMD), subsequent osteoporosis, and resultant fractures. The lit-
erature suggests an increased risk of fractures is reported with a daily dosage of prednisolone or
equivalent as low as 2.5–7.5 mg. [12] However, glucocorticoids use alone may not be a suffi-
cient reason for prescribing bisphosphonates in younger patients. The American College of
Rheumatology (ACR) 2012 recommendations for the prevention and treatment of glucocorti-
coid-induced osteoporosis suggest women with childbearing potential should have prevalent
fragility fracture in addition to more than 3 months glucocorticoids use as an indication for bis-
phosphonates treatment. [12]
There is not yet clear treatment guideline for osteoporosis in premenopausal women and
younger men due to limited data on the absolute risk of osteoporotic fracture and effectiveness
and safety of bisphosphonates in these patients. It is also unknown how commonly bisphos-
phonates are prescribed, which bisphosphonates are preferred, and what medical conditions or
medications that bisphosphonate users commonly have in adolescents and young adults. We
therefore undertook a large population-based cohort study to identify incident bisphosphonate
users aged 10–45 years and describe their characteristics and to assess time trends of bisphos-
phonate use over the past decade.
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Data Source
We conducted a cohort study using the claims data for the period January 1, 2003 to December
31, 2012, from United HealthCare,a commercial U.S. health plan, which insures primarily work-
ing adults and their family members. This database contains longitudinal claims information in-
cluding medical diagnoses, procedures, hospitalizations, physician visits, and pharmacy
dispensing on its approximately 14million subscribers across all states in the U.S. on a yearly
basis. Demographics of people in the database are similar to the U.S. general population for all
ages less than 65years, whereas the geographic distribution reflects the region-specific market
share of the health plan rather than the underlying population density. Patient informed consent
was not required as the dataset was de-identified to protect subject confidentiality. The study
protocol was approved by the Institutional Review Board of the Brigham and Women’sH o s p i t a l .
Study Cohort
The cohort is defined as all bisphosphonate initiators between 10 and 45 years of age on the
date of their first fill defined as the index date with a minimum of 12 months of enrollment
prior to the index date. An initiator was defined as having not used any generics or brand
names of bisphosphonate for the past 12 months. Bisphosphonates, either oral or intravenous,
include risedronate, ibandronate, zoledronate, etidronate, and pamidronate. Patients with any
malignancies prior to the index date were excluded.
Data Analysis
Baseline characteristics and health care utilization factors of the cohort were assessed 12
months preceding and including the index date. Age and sex were extracted from the individu-
al’s enrollment file and comorbidities were defined by appropriate ICD-9 CM codes and/or
medication dispensing records. Cumulative prednisone-equivalent doses were calculated for
systemic glucocorticoids over 3 and 12 months prior to initiation of bisphosphonates. Descrip-
tive statistics including proportions for categorical variables and means and standard devia-
tions for continuous variables were used to characterize the study cohort. A linear regression
assessed the trends of bisphosphonate use over the study period. A two-sided p-value less than
0.05 was considered statistically significant. All analyses were done using SAS 9.2 Statistical
Software (SAS Institute Inc., Cary, NC).
Results
Cohort Selection
During the study period, 12,568 bisphosphonates initiators were initially identified. 3,486
patients were excluded due to previous malignancies. In total, 9,082 patients were included in
analysis.
Patient Characteristics
The Table 1 shows the baseline characteristics of 9,082 bisphosphonate initiators aged 10–45
years. The most commonly used bisphosphonate was alendronate (53.5%), followed by risedro-
nate (29.8%), ibandronate (14.3%), zoledronic acid (1.2%), and etidronate or pamidronate
(1.2%). Most users were female (79.6%) and had frequent visits to physicians (15.214.6)
[meanSD] and high number of prescription drugs (9.46.9) in the 12 months prior to the
index date. Osteoporosis (41.2%) was the most common comorbidity, followed by
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Mean  SD or N (percentage)
Bisphosphonate Types
Alendronate 4,861 (53.5%)
Risedronate 2,704 (29.8%)
Ibandronate 1,303 (14.3%)
Zoledronate 110 (1.2%)
Etidronate or pamidronate 104 (1.2%)
Demographic
Age (years) 38.1  6.9
10–24 574 (6.3%)
25–34 1,650 (18.2%)
35–45 6,858 (75.5%)
Female 7,230 (79.6%)
Bisphosphonate indications
Osteoporosis 3,743 (41.2%)
Any fracture 981 (10.8%)
Inﬂammatory arthritis 651 (7.2%)
Systemic lupus erythematosus 539 (5.9%)
Inﬂammatory bowel disease 503 (5.5%)
Other bone diseases
a 96 (1.0%)
Comorbidities
Hyperlipidemia 2,287 (25.2%)
Anxiety or sleep disorder 1,615 (17.8%)
Hypertension 1,604 (17.7%)
Depression 1,583 (17.4%)
Thyroid disease 1,403 (15.4%)
Myopathy 910 (10.0%)
Diabetes 639 (7.0%)
Medications
Systemic glucocorticoids 3,538 (39.0%)
Antidepressants 2,060 (22.7%)
Proton pump inhibitors 1,603 (17.7%)
Other hormonal agents/HRT 1,276 (14.0%)
Sedatives 1,241 (13.7%)
Oral contraceptives 1,085 (11.9%)
Immunosuppressive drugs 834 (9.2%)
Anti-epileptics 712 (7.8%)
Inhaled steroids 404 (4.4%)
Antipsychotics 241 (2.7%)
Health Care Utilization
No. of outpatient visits 15.2  14.6
No. of specialty visits 10.9  12.5
No. of prescription drugs 9.4  6.9
Emergency room visit 1,270 (14.0%)
Acute hospitalization 1,764 (19.4%)
Bone density scan 2,632 (29.0%)
a Includes Paget’s disease of bone, osteogenesis imperfecta, and osteomalacia.
HRT = hormone replacement therapy
doi:10.1371/journal.pone.0115091.t001
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year prior to starting a bisphosphonate, 10.8% had a diagnosis of fracture and 29.0% had a
BMD measured. 14% patients used hormone replacement therapy (HRT) and 11.9% were on
oral contraceptives prior to initiating a bisphosphonate.
Thirty-nine percent used systemic glucocorticoids at baseline with an average 12-month
cumulative prednisone-equivalent dose [meanSD] of 2,66911,545 milligrams. The
3-month cumulative prednisone-equivalent dose [meanSD] was 1,4864,995 milligrams,
which is approximately 17 milligrams per day of prednisone for 90 days. Use of prescription
drugs such as antidepressants (22.7%), proton pump inhibitors (17.7%), and other hormones
(14%) were common.
Trend in Bisphosphonate Use
The number of bisphosphonate initiators significantly declined each year from 1,670 in 2004 to
344 in 2012 (p<0.001), despite the similar number of all patients aged 10–45 in the study data-
base (Fig. 1). Among all bisphosphonates initiators, the percentage of alendronate use fluctuat-
ed between 46% and 63%; use of etidronate and pamidronate remained less than 1% over time;
whereas risedronate use decreased dramatically from 43.4% in 2004 to 15.7% in 2012. Since
ibandronate’s introduction in 2005, its use increased fast and topped at 27% in 2007, and then
decreased slowly to 14.8% in 2012. Since zoledronate’s introduction in 2008, its use gradually
increased to 5.8% in 2012. Among all bisphosphonate initiators in 2004 (Table 2), 941 (56%)
patients had long-term use of glucocorticoid in the year prior to the index date. In total, 79%
bisphosphonate initiators had at least one potential bisphosphonate indication, including oste-
oporosis (40%), any fracture (11%), inflammatory arthritis (9%), systemic lupus erythematosus
(9%), inflammatory bowel disease (9%), and other bone diseases (1%). The percentage of these
diagnoses among bisphosphonate initiators remained stable over the study period.
Figure 1. The annual relative contribution to the 9,082 bisphosphonate initiators identified over the entire period of interest (2003–2012). The dotted
line represents the total number of patients aged 10 to 45 years in the study database.
doi:10.1371/journal.pone.0115091.g001
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This large population-based cohort study showed that the use of bisphosphonates was uncom-
mon in adolescents and young adults in the U.S. and significantly decreased over time. Further-
more, this study suggests a potential gap in understanding clinical practice patterns in treating
young patients at a possible risk for osteoporosis, as some bisphosphonate initiators were with
no clear indication for bisphosphonate treatment recorded in the year prior to initiating a
bisphosphonate.
Unlike well-established diagnosis and treatment of osteoporosis in postmenopausal women
and older men, there is uncertainty in the management of osteoporosis among young patients.
To date, little is known whether benefits of bisphosphonates in preventing bone loss would out-
weigh other potential risks among the young patient population. We also lack the evidence re-
garding when treatment should stop. Some experts suggest a drug holiday should be considered
after several years of treatment, although there is no official recommendation to guide clini-
cians.[13] Use of bisphosphonates should be avoided for certain patient groups, such as preg-
nant women or women during lactation due to the lack of safety data in pregnancy.
From Fig. 1, we observed the number of bisphosphonates initiators per year among young
patients (aged 10 to 45) decreased significantly from 1,670 to 344 over the follow-up period.
This trend does not appear to be related to changes in the number of total patients or long-
term GC users in the study database, since it remained relatively stable compared to the num-
ber of bisphosphonates initiators per year. Although it is speculative, this downward trend in
use of bisphosphonates may be related to growing concerns over side effects of bisphospho-
nates over the past several years.
Systemic glucocorticoids use is common in any age group, [14] and glucocorticoid-induced
osteoporosis (GIOP) is a major side effect among long-term glucocorticoids users. As the ACR
2010 Recommendations for the Prevention and Treatment of GIOP focuses mainly on older
patients, [12] it is unclear how to best prevent bone loss and future fracture among younger pa-
tients at risk for osteoporosis. Current guidelines recommend a pharmacologic treatment in-
cluding bisphosphonates only for patients exposed to long-term glucocorticoids who have a
fragility fracture. [12] Some experts further recommend osteoporosis treatment in premeno-
pausal women who need a long-term glucocorticoids therapy with a significant decline in
BMD for age or a Z-score below -2.0.[15] Given the low proportions of fracture diagnosis, glu-
cocorticoids use, and BMD examination among bisphosphonates initiators in our study, there
may be a gap between the current guidelines and clinical practice.
Table 2. Potential indications for initiating bisphosphonate treatment.
Potential indications for initiating bisphosphonate treatment (%)
Number of
bisphosphonate
initiators
Number of GC users in
the study database
Osteoporosis Any
Fracture
Arthritis SLE Bowel
Disease
Other Bone
Disease
GC
Users
2004 1,670 379,492 40.2 11.5 8.7 8.7 9.0 1.0 56.3
2005 1,613 385,374 41.9 11.7 8.4 7.2 7.9 1.2 49.7
2006 1,414 397,942 42.2 10.4 8.8 7.4 8.3 1.2 45.3
2007 1,079 392,526 47.2 12.0 11.3 8.8 7.6 1.1 53.4
2008 1,036 410,359 49.3 12.5 10.7 9.7 8.1 1.6 55.3
2009 862 430,834 44.9 13.2 10.9 10.0 7.2 1.5 51.4
2010 655 410,074 46.1 12.2 9.3 8.4 6.0 1.2 51.0
2011 409 403,453 51.6 17.1 14.9 11.5 11.2 2.0 59.4
2012 344 391,152 39.8 12.5 8.1 7.3 6.7 0.9 34.9
doi:10.1371/journal.pone.0115091.t002
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tors and the relatively long and recent study period to observe the temporal trend in bisphos-
phonates use. This study also has several limitations. First, the study was not designed to
determine the reasons for a decrease in bisphosphonate use. Second, even though we used a
year prior to bisphosphonate initiation to assess clinical characteristics including potential in-
dications for bisphosphonate treatment, the 1-year time period may not be sufficiently long.
Third, there is potential under ascertainment of other indications for bisphosphonates, such as
giant cell lesions of the jaw, fibrous dysplasia, Gaucher’s disease and other uncommon meta-
bolic bone disease due to incomplete recording of these diagnoses in the claims database.
Fourth, this study may not be generalizable because this study included a commercially insured
population only. Lastly, we are unable to check whether patients underwent a BMD testing if
they did not claim the insurer for the test.
In conclusion, this study shows that use of bisphosphonates in patients aged 10–45 was un-
common and significantly decreased over the past decade in the U.S. This study also suggests a
potential gap in understanding clinical practice patterns in treating young patients at a possible
risk for osteoporosis, as some bisphosphonate initiators were with no clear indication for bis-
phosphonate treatment recorded in the year prior to initiating a bisphosphonate. The reason
for the decline in the use of bisphosphonates should be further examined, as it cannot be ex-
plained by the change in the prevalence of potential risk factors for osteoporosis in the popula-
tion. Furthermore, there is a need to evaluate factors determining bisphosphonates initiation
among young patients including women of childbearing age and to assess the effectiveness and
safety of bisphosphonates in the under-studied population.
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